Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Extended synaptotagmin-3 (ESYT3) is a membrane-anchored protein of the endoplasmic reticulum (ER) that tethers the ER to the plasma membrane (PM) via its C2 domains and mediates lipid transfer between these membranes through its synaptotagmin-like mitochondrial-lipid binding protein (SMP) domain[1][2][3]. ESYT3 forms part of the extended synaptotagmin family, which participates in constitutive and regulated ER–PM contact formation, helping maintain plasma membrane lipid homeostasis and facilitating inter-organelle communication in eukaryotic cells[1][2]. ESYT3 is predicted to bind calcium ions and phospholipids, and plays a non-redundant role in specific cellular contexts for organizing membrane contact sites; however, knockout studies in mammals have so far shown minor or context-dependent phenotypes[4][5]. There is currently no evidence of ESYT3 serving as a direct therapeutic target, nor is there documentation of marketed drugs acting on it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Extended synaptotagmin-3 (ESYT3).